



Clinical trial results:

An Interventional Efficacy and Safety, Phase 2/3, Double-Blind, 2-Arm Study to Investigate Orally Administered PF-07321332/Ritonavir Compared With Placebo in Non hospitalized Symptomatic Adult Participants With COVID-19 Who are at Increased Risk of Progressing to Severe Illness

Summary

EudraCT number	2021-002895-38
Trial protocol	ES CZ HU BG
Global end of trial date	26 April 2022

Results information

Result version number	v1 (current)
This version publication date	10 May 2023
First version publication date	10 May 2023

Trial information

Trial identification

Sponsor protocol code	C4671005
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04960202
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Pfizer Inc.
Sponsor organisation address	235 E42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer Inc., 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 June 2022
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	26 April 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To compare the efficacy of PF-07321332/ritonavir to placebo for the treatment of COVID-19 in non-hospitalised symptomatic adult subjects with COVID-19 who are at increased risk of progression to severe disease.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 July 2021
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	3 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 8
Country: Number of subjects enrolled	Brazil: 7
Country: Number of subjects enrolled	Bulgaria: 444
Country: Number of subjects enrolled	Colombia: 2
Country: Number of subjects enrolled	Czechia: 3
Country: Number of subjects enrolled	Hungary: 8
Country: Number of subjects enrolled	India: 191
Country: Number of subjects enrolled	Japan: 6
Country: Number of subjects enrolled	Korea, Republic of: 19
Country: Number of subjects enrolled	Malaysia: 4
Country: Number of subjects enrolled	Mexico: 258
Country: Number of subjects enrolled	Poland: 3
Country: Number of subjects enrolled	Puerto Rico: 3
Country: Number of subjects enrolled	Russian Federation: 10
Country: Number of subjects enrolled	South Africa: 13
Country: Number of subjects enrolled	Spain: 2
Country: Number of subjects enrolled	Thailand: 80

Country: Number of subjects enrolled	Turkey: 44
Country: Number of subjects enrolled	Ukraine: 203
Country: Number of subjects enrolled	United States: 783
Worldwide total number of subjects	2091
EEA total number of subjects	460

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1828
From 65 to 84 years	263
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

2256 subjects signed the informed consent form (ICF). Out of these 2256 subjects, 130 were screen failures who did not meet the study criteria and were not enrolled. There were 13 subjects who were not screen failure but not randomized due to withdrew consent or other reasons. Of the 2113 randomised subjects, only 2091 received study treatment.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Carer, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	PF-07321332 300 mg and Ritonavir 100 mg

Arm description:

Subjects with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received 300 milligrams (mg) PF-07321332 coadministered with 100 mg ritonavir orally, every 12 hours (q12h) for 5 days. Subjects were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24.

Arm type	Experimental
Investigational medicinal product name	Ritonavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

100mg for every 12 hours for 5 days

Investigational medicinal product name	PF-07321332
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

300 mg every 12 hours for 5 days

Arm title	Placebo
------------------	---------

Arm description:

Subjects with SARS-CoV-2 infection received placebo orally, q12h for 5 days. Subjects were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24.

Arm type	Placebo
Investigational medicinal product name	Placebo for PF-07321332
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

every 12hours for 5 days

Investigational medicinal product name	Placebo for ritonavir
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

every 12hours for 5 days

Number of subjects in period 1	PF-07321332 300 mg and Ritonavir 100 mg	Placebo
Started	1038	1053
Completed	976	979
Not completed	62	74
Consent withdrawn by subject	37	43
Death	-	15
Not specified	5	-
Lost to follow-up	20	16

Baseline characteristics

Reporting groups

Reporting group title	PF-07321332 300 mg and Ritonavir 100 mg
Reporting group description:	
Subjects with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received 300 milligrams (mg) PF-07321332 coadministered with 100 mg ritonavir orally, every 12 hours (q12h) for 5 days. Subjects were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24.	
Reporting group title	Placebo
Reporting group description:	
Subjects with SARS-CoV-2 infection received placebo orally, q12h for 5 days. Subjects were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24.	

Reporting group values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo	Total
Number of subjects	1038	1053	2091
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-44 years)	534	499	1033
From (45-59 years)	306	316	622
Form (60-64 years)	69	104	173
From (65-74 years)	96	103	199
more than 75 years	33	31	64
Age Continuous			
Units: Years			
arithmetic mean	44.86	45.96	
standard deviation	± 15.37	± 15.56	-
Sex: Female, Male			
Units: Participants			
Female	522	515	1037
Male	516	538	1054
Race			
Units: Subjects			
American Indian or Alaska Native	95	94	189
Asian	153	156	309
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	52	35	87
White	728	756	1484
More than one race	1	2	3
Unknown or Not Reported	9	10	19
Ethnicity			

Units: Subjects			
Hispanic or Latino	425	439	864
Not Hispanic or Latino	608	607	1215
Unknown or Not Reported	5	7	12

End points

End points reporting groups

Reporting group title	PF-07321332 300 mg and Ritonavir 100 mg
Reporting group description: Subjects with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received 300 milligrams (mg) PF-07321332 coadministered with 100 mg ritonavir orally, every 12 hours (q12h) for 5 days. Subjects were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24.	
Reporting group title	Placebo
Reporting group description: Subjects with SARS-CoV-2 infection received placebo orally, q12h for 5 days. Subjects were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24.	

Primary: Percentage of Subjects With Covid-19 Related Hospitalisation or Death From any Cause Through Day 28- Modified Intent-To-Treat (mITT) Population

End point title	Percentage of Subjects With Covid-19 Related Hospitalisation or Death From any Cause Through Day 28- Modified Intent-To-Treat (mITT) Population
End point description: Percentage of subjects with COVID-19 related hospitalization or death from any cause during the first 28 days of the study was estimated using the Kaplan-Meier (KM) method. Using KM method, survival probability for each time interval was calculated as the number of subjects surviving divided by the number of subjects at risk. Subjects who had the event, dropped out, or moved out were not counted as "at risk" i.e., subjects who were lost were considered "censored" and were not counted in the denominator. mITT population included all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic monoclonal antibody (mAb) treatment and were treated <=3 days of COVID-19 onset.	
End point type	Primary
End point timeframe: From Day 1 to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	671	647		
Units: Percentage of Subjects				
number (confidence interval 95%)	0.752 (0.313 to 1.796)	6.888 (5.172 to 9.146)		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description: The difference of the percentage in the 2 treatment groups and its 95% confidence interval, and p-value based on normal approximation of the data are presented.	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo

Number of subjects included in analysis	1318
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Normal approximation
Parameter estimate	Percentage difference
Point estimate	-6.137
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.208
upper limit	-4.066
Variability estimate	Standard error of the mean
Dispersion value	1.057

Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs)

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
-----------------	---

End point description:

An adverse event (AE) was any untoward medical occurrence in a subject, temporarily associated with the use of study intervention, whether or not considered related to the study intervention. Serious adverse event (SAE) was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalisation or prolongation of existing hospitalisation; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect; a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical events. AEs included both SAEs and all non-SAEs. An AE was considered as TEAE if the event started on or after start date of study intervention. Safety analysis set (SAS) included all subjects who received at least one dose of study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of study intervention (Day 1) up to end of safety follow-up (Day 34)

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Subjects	228	256		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With AEs Leading to Discontinuation and Serious Adverse Events (SAEs)

End point title	Number of Subjects With AEs Leading to Discontinuation and
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject, temporarily associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalisation or prolongation of existing hospitalisation; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect; a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic and other important medical events. SAS population included all subjects who were randomised and took at least one dose of investigational product.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of study intervention (Day 1) up to end of safety follow-up (Day 34)

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Subjects				
AEs leading to study discontinuation	0	13		
SAEs	18	71		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Covid-19 Related Hospitalisation or Death From any Cause Through Day 28- Modified Intent-To-Treat 1 (mITT1) Population

End point title	Percentage of Subjects With Covid-19 Related Hospitalisation or Death From any Cause Through Day 28- Modified Intent-To-Treat 1 (mITT1) Population
-----------------	--

End point description:

Percentage of Subjects with COVID-19 related hospitalisation or death from any cause during the first 28 days of the study was estimated using the Kaplan-Meier method. mITT1 population included all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 to Day 28

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	977	989		
Units: Percentage of Subjects				

number (confidence interval 95%)	0.933 (0.487 to 1.786)	6.571 (5.180 to 8.318)		
----------------------------------	------------------------	------------------------	--	--

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
The difference of the percentage in the 2 treatment groups and its 95% confidence interval, and p-value based on normal approximation of the data are presented.	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1966
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Normal approximation
Parameter estimate	Percentage difference
Point estimate	-5.638
Confidence interval	
level	95 %
sides	2-sided
lower limit	-7.308
upper limit	-3.967
Variability estimate	Standard error of the mean
Dispersion value	0.852

Secondary: Time to Sustained Alleviation of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT Population

End point title	Time to Sustained Alleviation of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT Population
End point description:	
Sustained alleviation of all targeted COVID-19 signs/symptoms defined as event occurring on first 4 consecutive days when all symptoms scored as moderate or severe at enrollment were scored as mild or absent and those scored mild or absent at enrollment were scored as absent. First day of the 4 consecutive-day period=date of first event. Time to sustained alleviation (event)=first event date minus first dose date plus 1, for subjects with event. For subjects who completed Day 28 or discontinued study before Day 28 without sustained alleviation (censored), time=censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first. mITT population: all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated <=3 days of COVID-19 onset. Here "N"=subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	666	645		
Units: Days				
median (confidence interval 95%)	12.00 (12.00 to 13.00)	15.00 (13.00 to 16.00)		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Analysis of treatment effect on time to sustained alleviation is based on Cox proportional hazard (PH) model with treatment and geographic region effects as independent variables, and baseline SARS-CoV-2 serology status and baseline viral load (<4 logarithm to base 10 [log10] copies/milliliter [mL], >=4 log10 copies/mL) as covariates.	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1311
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0001
Method	Cox Proportional Hazard Model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.294
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.136
upper limit	1.476

Secondary: Time to Sustained Alleviation of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT1 Population

End point title	Time to Sustained Alleviation of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT1 Population
End point description:	
Sustained alleviation of all targeted COVID-19 signs/symptoms defined as event occurring on first 4 consecutive days when all symptoms scored as moderate or severe at enrollment were scored as mild or absent and those scored mild or absent at enrollment were scored as absent. First day of the 4 consecutive-day period=date of first event. Time to sustained alleviation (event)=first event date minus first dose date plus 1, for subjects with event. For subjects who completed Day 28 or discontinued study before Day 28 without sustained alleviation (censored), time=censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first. mITT1 population: all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. Here "N"=subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	970	986		
Units: Days				
median (confidence interval 95%)	13.00 (12.00 to 13.00)	15.00 (14.00 to 16.00)		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Analysis of treatment effect on time to sustained alleviation is based on Cox PH model with treatment and geographic region effects as independent variables, and symptom onset duration (≤ 3 , > 3), baseline SARS-CoV-2 serology status and baseline viral load ($< 4 \log_{10}$ copies/mL, $\geq 4 \log_{10}$ copies/mL) as covariates.	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1956
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Cox Proportional Hazard Model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.266
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.134
upper limit	1.412

Secondary: Time to Sustained Alleviation of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT2 Population

End point title	Time to Sustained Alleviation of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT2 Population
End point description:	
Sustained alleviation of all targeted COVID-19 signs/symptoms defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. First day of the 4 consecutive-day period=date of first event. Time to sustained alleviation (event)=first event date minus first dose date plus 1, for subjects with event. For subjects who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time=censoring date (last date on which symptom alleviation was assessed) minus first dose date plus 1 or Day 25 whichever occurred first. mITT2 population: all subjects who were randomised and took at least one dose of study intervention. Here "N"=subjects evaluable for this endpoint.	
End point type	Secondary

End point timeframe:

From Day 1 (baseline) to Day 28

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1031	1050		
Units: Days				
median (confidence interval 95%)	13.00 (12.00 to 13.00)	16.00 (15.00 to 17.00)		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Analysis of treatment effect on time to sustained alleviation is based on Cox PH model with treatment and geographic region effects as independent variables, and symptom onset duration (≤ 3 , > 3), COVID-19 mAb treatment (Yes/No), baseline SARS-CoV-2 serology status and baseline viral load (< 4 log ₁₀ copies/mL, ≥ 4 log ₁₀ copies/mL) as covariates.	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	2081
Analysis specification	Pre-specified
Analysis type	
P-value	< 0.0001
Method	Cox Proportional Hazard Model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.258
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.131
upper limit	1.4

Secondary: Percentage of Subjects With Severe Covid-19 Signs and Symptoms Through Day 28- mITT Population

End point title	Percentage of Subjects With Severe Covid-19 Signs and Symptoms Through Day 28- mITT Population
-----------------	--

End point description:

Subjects were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale ranging from 0 to 3, higher scores indicated more severity. Scale was reported as 0=no symptoms, 1=mild, 2=moderate and 3=severe. A subject with severe score for any targeted symptoms post-baseline was counted as severe. Percentage of subjects with severe Covid-19 signs and symptoms were reported. mITT population: all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤ 3 days of COVID-19 onset. Here "N"=signifies subjects evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
From Day 1 to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	666	645		
Units: Percentage of Subjects				
number (not applicable)	18.168	20.775		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Odds ratio, 95% CI and p-value were computed from a logistic regression model including main effects of treatment, geographic region, baseline SARS-CoV-2 serology status and baseline viral load (< 4 log10 copies/mL, >= 4 log10 copies/mL).	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1311
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.3473
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.871
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.652
upper limit	1.162

Secondary: Percentage of Subjects With Severe Covid-19 Signs and Symptoms Through Day 28- mITT1 Population

End point title	Percentage of Subjects With Severe Covid-19 Signs and Symptoms Through Day 28- mITT1 Population
End point description:	
Subjects were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale ranging from 0 to 3, higher scores indicated more severity. The scale was reported as 0= no symptoms, 1=mild, 2=moderate and 3=severe. A subject with severe score for any targeted symptoms post-baseline was counted as severe. Percentage of subjects with severe Covid-19 signs and symptoms were reported. mITT1 population: all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. Here "N"=signifies subjects evaluable for this endpoint.	
End point type	Secondary

End point timeframe:
From Day 1 to Day 28

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	970	986		
Units: Percentage of Subjects				
number (not applicable)	19.691	21.298		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Odds ratio, 95% CI and p-value were computed from a logistic regression model including main effects of treatment, geographic region, symptom onset duration (≤ 3 , > 3), baseline SARS-CoV-2 serology status and baseline viral load ($< 4 \log_{10}$ copies/mL, $\geq 4 \log_{10}$ copies/mL).	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1956
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5762
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.936
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.74
upper limit	1.182

Secondary: Time to Sustained Resolution of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT Population

End point title	Time to Sustained Resolution of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT Population
End point description:	
Sustained resolution was defined as when all targeted symptoms were scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for subjects with event. For subjects who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first. mITT population: all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤ 3 days of COVID-19 onset. Here "N" signifies subjects evaluable for this endpoint.	
End point type	Secondary

End point timeframe:

From Day 1 (baseline) to Day 28

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	686	674		
Units: Days				
median (confidence interval 95%)	16.00 (14.00 to 17.00)	18.00 (17.00 to 20.00)		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Analysis of treatment effect on time to sustained resolution is based on Cox PH model with treatment and geographic region effects as independent variables, and baseline SARS-CoV-2 serology status and baseline viral load (<4 log10 copies/mL, >=4 log10 copies/mL) as covariates.	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1360
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0053
Method	Cox Proportional Hazard Model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.219
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.061
upper limit	1.401

Secondary: Percentage of Subjects With Severe Covid-19 Signs and Symptoms Through Day 28- mITT2 Population

End point title	Percentage of Subjects With Severe Covid-19 Signs and Symptoms Through Day 28- mITT2 Population
End point description:	
Subjects were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale ranging from 0 to 3, higher scores indicated more severity. The scale was reported as 0= no symptoms, 1=mild, 2=moderate and 3=severe. A subject with severe score for any targeted symptoms post-baseline was counted as severe. Percentage of subjects with severe Covid-19 signs and symptoms were reported. mITT2 population included all subjects who were randomised and took at least one dose of study intervention. Here "N"=signifies subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe:	
From Day 1 to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1031	1050		
Units: Percentage of Subjects				
number (not applicable)	20.660	21.810		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Odds ratio, 95% CI and p-value were computed from a logistic regression model including main effects of treatment, geographic region, symptom onset duration (≤ 3 , > 3), COVID-19 mAb treatment (Yes/No), baseline SARS-CoV-2 serology status and baseline viral load ($< 4 \log_{10}$ copies/mL, $\geq 4 \log_{10}$ copies/mL).	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	2081
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.7807
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.969
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.773
upper limit	1.213

Secondary: Time to Sustained Resolution of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT1 Population

End point title	Time to Sustained Resolution of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT1 Population
End point description:	
Sustained resolution was defined as when all targeted symptoms were scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for subjects with event. For subjects who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first. mITT1 population: all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. Here "N" signifies subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	970	986		
Units: Days				
median (confidence interval 95%)	16.00 (15.00 to 18.00)	19.00 (18.00 to 20.00)		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Analysis of treatment effect on time to sustained resolution is based on Cox PH model with treatment and geographic region effects as independent variables, and symptom onset duration (≤ 3 , > 3), baseline SARS-CoV-2 serology status and baseline viral load ($< 4 \log_{10}$ copies/mL, $\geq 4 \log_{10}$ copies/mL) as covariates.	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1956
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0022
Method	Cox Proportional Hazard Model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.068
upper limit	1.348

Secondary: Time to Sustained Resolution of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT2 Population

End point title	Time to Sustained Resolution of all Targeted COVID-19 Signs and Symptoms Through Day 28- mITT2 Population
End point description:	
Sustained resolution was defined as when all targeted symptoms were scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for subjects with event. For subjects who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first. mITT2 population: all subjects who were randomised and took at least one dose of study intervention. Here "N" =signifies subjects evaluable for this endpoint.	
End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1031	1050		
Units: Days				
median (confidence interval 95%)	17.000 (15.000 to 18.000)	19.000 (18.000 to 20.000)		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Analysis of treatment effect on time to sustained resolution is based on Cox PH model with treatment and geographic region effects as independent variables, and symptom onset duration (≤ 3 , > 3), COVID-19 mAb treatment (Yes/No), baseline SARS-CoV-2 serology status and baseline viral load (< 4 log ₁₀ copies/mL, ≥ 4 log ₁₀ copies/mL) as covariates.	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	2081
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.0021
Method	Cox Proportional Hazard Model
Parameter estimate	Hazard ratio (HR)
Point estimate	1.194
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.066
upper limit	1.337

Secondary: Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT Population

End point title	Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT Population
-----------------	---

End point description:

Sustained alleviation of each targeted COVID-19 signs/symptoms=event occurring on first 4 consecutive days when each symptom scored moderate or severe at enrollment were scored as mild or absent and those scored mild or absent were scored as absent. First day of 4 consecutive day period=date of first event. Time to sustained alleviation (event)=first event date - first dose date +1, for subjects with event. Subjects who completed Day 28 or discontinued study before Day 28 without sustained alleviation (censored), time=censoring date - first dose date +1 or Day 25 whichever occurred first. mITT population: randomised subjects who took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and treated ≤ 3 days of COVID-19 onset. "N"=subjects evaluable for endpoint; "n"=subjects evaluable for each specified category.

End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	671	647		
Units: Days				
median (confidence interval 95%)				
Muscle or body aches (n=528,506)	6.000 (5.000 to 7.000)	7.000 (6.000 to 8.000)		
Shortness of breath (n=277,290)	6.000 (5.000 to 7.000)	8.000 (6.000 to 9.000)		
Chills or shivering (n=412,376)	3.000 (3.000 to 4.000)	5.000 (4.000 to 5.000)		
Cough (n=539,525)	8.000 (8.000 to 9.000)	10.000 (9.000 to 11.000)		
Diarrhea (n=165,143)	4.000 (3.000 to 6.000)	4.000 (3.000 to 6.000)		
Feeling hot or feverish (n=420,398)	3.000 (3.000 to 4.000)	5.000 (4.000 to 5.000)		
Headache (n=494,453)	5.000 (4.000 to 5.000)	7.000 (6.000 to 8.000)		
Nausea (n=221,220)	4.000 (3.000 to 5.000)	5.000 (4.000 to 7.000)		
Stuffy or runny nose (n=466,440)	6.000 (5.000 to 7.000)	7.000 (7.000 to 8.000)		
Sore throat (n=373,347)	5.000 (4.000 to 5.000)	6.000 (5.000 to 7.000)		
Vomit (n=69,70)	3.000 (2.000 to 4.000)	3.000 (2.000 to 5.000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT1 Population

End point title	Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT1 Population
-----------------	--

End point description:

Sustained alleviation of each targeted COVID-19 signs/symptoms = event occurring on the first 4 consecutive days when each symptom scored as moderate or severe at enrollment were scored as mild or absent and those scored mild or absent at enrollment were scored as absent. First day of the 4 consecutive-day period = date of first event. Time to sustained alleviation (event) = first event date - first dose date + 1, for subjects with event. For subjects who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time = censoring date (last date on which symptom alleviation was assessed) - first dose date + 1 or Day 25 whichever occurred first. mITT1 population: all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. Here "N" = subjects evaluable for this endpoint. Here, "n" = subjects evaluable for each specified category.

End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	977	989		
Units: Days				
median (confidence interval 95%)				
Muscle or body aches (n=772,778)	6.000 (5.000 to 7.000)	7.000 (7.000 to 8.000)		
Shortness of breath (n=423,451)	6.000 (5.000 to 7.000)	8.000 (7.000 to 10.000)		
Chills or shivering (n=584,578)	3.000 (3.000 to 4.000)	5.000 (4.000 to 5.000)		
Cough (n=791,816)	9.000 (8.000 to 9.000)	10.000 (9.000 to 11.000)		
Diarrhea (n=262,246)	5.000 (4.000 to 6.000)	4.000 (3.000 to 5.000)		
Feeling hot or feverish (n=603,613)	3.000 (3.000 to 4.000)	5.000 (4.000 to 6.000)		
Headache (n=709,709)	5.000 (5.000 to 6.000)	7.000 (7.000 to 8.000)		
Nausea (n=348,363)	5.000 (4.000 to 6.000)	6.000 (5.000 to 7.000)		
Stuffy or runny nose (n=690,684)	6.000 (5.000 to 7.000)	7.000 (7.000 to 8.000)		
Sore throat (n=548,560)	5.000 (4.000 to 5.000)	6.000 (5.000 to 7.000)		
Vomit (n=116,115)	3.000 (2.000 to 4.000)	3.000 (2.000 to 5.000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT2 Population

End point title	Time to Sustained Alleviation of Each Targeted COVID-19 Signs and Symptoms- mITT2 Population
-----------------	--

End point description:

Sustained alleviation of each targeted COVID-19 signs/symptoms = the event occurring on the first 4 consecutive days when each symptom scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. The first day of the 4 consecutive-day period = date of first event. Time to sustained alleviation (event)=as first event date - first dose date+ 1, for subjects with event. For subjects who completed Day 28 or discontinued the study before Day 28 without sustained alleviation (censored), time =censoring date (last date on which symptom alleviation was assessed) - first dose date +1 or Day 25 whichever occurred first. mITT2 population: all subjects who were randomised and took at least one dose of study intervention. Here, "n" = subjects evaluable for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 (baseline) to Day 28

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Days				
median (confidence interval 95%)				
Muscle or body aches (n=821,830)	6.000 (6.000 to 7.000)	8.000 (7.000 to 9.000)		
Shortness of breath (n=459,487)	6.000 (5.000 to 7.000)	9.000 (8.000 to 10.000)		
Chills or shivering (n=627,620)	3.000 (3.000 to 4.000)	5.000 (4.000 to 5.000)		
Cough (n=843,874)	9.000 (8.000 to 9.000)	10.000 (9.000 to 11.000)		
Diarrhea (n=287,276)	5.000 (4.000 to 6.000)	4.000 (3.000 to 5.000)		
Feeling hot or feverish (n=649,656)	3.000 (3.000 to 4.000)	5.000 (4.000 to 5.000)		
Headache (n=759,760)	5.000 (5.000 to 6.000)	7.000 (7.000 to 8.000)		
Nausea (n=374,390)	5.000 (4.000 to 6.000)	6.000 (5.000 to 7.000)		
Stuffy or runny nose (n=739,738)	6.000 (5.000 to 7.000)	7.000 (7.000 to 8.000)		
Sore throat (n=582,607)	5.000 (4.000 to 5.000)	6.000 (5.000 to 7.000)		
Vomit (n=132,135)	3.000 (3.000 to 4.000)	3.000 (2.000 to 5.000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT Population

End point title	Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT Population
-----------------	--

End point description:

Sustained resolution was defined as when each targeted symptom was scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for subjects with event. For subjects who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date (last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first. mITT population included all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤3 days of COVID-19 onset. Here "N" = subjects evaluable for this endpoint. Here, "n" = subjects evaluable for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 (baseline) to Day 28

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	671	647		
Units: Days				
median (confidence interval 95%)				
Muscle or body aches (n=528,506)	9.000 (8.000 to 11.000)	12.000 (11.000 to 13.000)		
Shortness of breath (n=227,290)	8.000 (7.000 to 9.000)	11.000 (10.000 to 14.000)		
Chills or shivering (n=412,376)	5.000 (4.000 to 5.000)	7.000 (6.000 to 8.000)		
Cough (n=539,525)	13.000 (12.000 to 13.000)	15.000 (14.000 to 16.000)		
Diarrhea (n=165,143)	6.000 (5.000 to 8.000)	6.000 (4.000 to 9.000)		
Feeling hot or feverish (n=420,398)	5.000 (4.000 to 5.000)	7.000 (6.000 to 8.000)		
Headache (n=494,453)	8.000 (8.000 to 9.000)	11.000 (9.000 to 12.000)		
Nausea (n=221,220)	5.000 (4.000 to 7.000)	7.000 (6.000 to 10.000)		
Stuffy or runny nose (n=466,440)	9.000 (9.000 to 10.000)	10.000 (9.000 to 11.000)		
Sore throat (n=373,347)	7.000 (6.000 to 7.000)	9.000 (8.000 to 10.000)		
Vomit (n=69,70)	3.000 (2.000 to 5.000)	3.000 (2.000 to 5.000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT1 Population

End point title	Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT1 Population
-----------------	---

End point description:

Sustained resolution was defined as when each targeted symptom was scored as absent for 4 consecutive days. Time to sustained resolution (event)= First event date - first dose date + 1, for subjects with event. For subjects who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time =censoring date (last date on which symptom resolution was assessed) - first dose date +1 or Day 25 whichever occurred first. mITT1 population: all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. Here "N"=subjects evaluable for this endpoint. Here, "n"=Subjects evaluable for each specified category. 99999 indicates

the number of subjects with events available was not sufficient for the calculation of the limits using KM.

End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	977	989		
Units: Days				
median (confidence interval 95%)				
Muscle or body aches (n=772,778)	9.000 (8.000 to 10.000)	12.000 (11.000 to 13.000)		
Shortness of breath (n=423,451)	9.000 (8.000 to 10.000)	12.000 (11.000 to 15.000)		
Chills or shivering (n=584,578)	5.000 (4.000 to 5.000)	7.000 (6.000 to 8.000)		
Cough (n=791,816)	13.000 (12.000 to 14.000)	15.000 (14.000 to 17.000)		
Diarrhea (n=262,246)	6.000 (6.000 to 8.000)	6.000 (5.000 to 8.000)		
Feeling hot or feverish (n=603,613)	5.000 (-99999 to 99999)	7.000 (6.000 to 8.000)		
Headache (n=709,709)	9.000 (8.000 to 10.000)	11.000 (10.000 to 13.000)		
Nausea (n=348,363)	7.000 (6.000 to 8.000)	7.000 (6.000 to 9.000)		
Stuffy or runny nose (n=690,684)	9.000 (9.000 to 10.000)	11.000 (9.000 to 11.000)		
Sore throat (n=548,560)	7.000 (6.000 to 8.000)	9.000 (8.000 to 10.000)		
Vomit (n=116,115)	3.000 (3.000 to 5.000)	3.000 (2.000 to 5.000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT2 Population

End point title	Time to Sustained Resolution of Each Targeted COVID-19 Signs and Symptoms- mITT2 Population
-----------------	---

End point description:

Sustained resolution was defined as when each targeted symptom was scored as absent for 4 consecutive days. Time to sustained resolution (event) was calculated as first event date minus first dose date plus 1, for participants with event. For participants who completed Day 28 or discontinued the study before Day 28 without sustained resolution (censored), time was calculated as censoring date

(last date on which symptom resolution was assessed) minus first dose date plus 1 or Day 25 whichever occurred first. mITT2 population=all subjects who were randomized and took at least one dose of study intervention. Here, "n" = subjects evaluable for each specified category.

End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Days				
median (confidence interval 95%)				
Muscle or body aches (n=821,830)	9.000 (8.000 to 10.000)	12.000 (11.000 to 13.000)		
Shortness of breath (n=459,487)	9.000 (8.000 to 10.000)	13.000 (11.000 to 15.000)		
Chills or shivering (n=627,620)	5.000 (4.000 to 5.000)	7.000 (6.000 to 8.000)		
Cough (n=843,874)	13.000 (12.000 to 14.000)	15.000 (14.000 to 17.000)		
Diarrhea (n=287,276)	6.000 (6.000 to 8.000)	6.000 (5.000 to 8.000)		
Feeling hot or feverish (n=649,656)	5.000 (5.000 to 6.000)	7.000 (6.000 to 8.000)		
Headache (n=759,760)	9.000 (9.000 to 10.000)	11.000 (10.000 to 13.000)		
Nausea (n=374,390)	7.000 (6.000 to 8.000)	7.000 (6.000 to 9.000)		
Stuffy or runny nose (n=739,738)	9.000 (9.000 to 10.000)	11.000 (10.000 to 12.000)		
Sore throat (n=582,607)	7.000 (6.000 to 8.000)	9.000 (8.000 to 10.000)		
Vomit (n=132,135)	3.000 (3.000 to 5.000)	4.000 (3.000 to 5.000)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT1 Population

End point title	Number of Subjects With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT1 Population
-----------------	---

End point description:

Subjects were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale where 0 = no symptoms; 1= mild; 2= moderate; and 3= severe. Vomiting and diarrhea were each rated on a 4-point frequency scale where 0= no occurrence, 1= mild for 1 to 2 times, 2= moderate for 3 to 4 times, and 3= severe for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline).mITT1 population included all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. Here 'N' signifies subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 (baseline) to Day 28

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	970	986		
Units: Subjects	735	737		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
-----------------------------------	---

Statistical analysis description:

Odds ratio, 95% CI and p-value were computed from a logistic regression model including main effects of treatment, geographic region, symptom onset duration (≤ 3 , > 3), baseline SARS-CoV-2 serology status and baseline viral load ($< 4 \log_{10}$ copies/mL, $\geq 4 \log_{10}$ copies/mL).

Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1956
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.6379
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.053
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.85
upper limit	1.303

Secondary: Number of Subjects With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT Population

End point title	Number of Subjects With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT Population
-----------------	--

End point description:

Subjects were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale where 0 = no symptoms; 1= mild; 2= moderate; and 3= severe. Vomiting and diarrhea were each rated on a 4-point frequency scale where 0= no occurrence, 1= mild for 1 to 2 times, 2= moderate for 3 to 4 times, and 3= severe for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline).mITT population included all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated <=3 days of COVID-19 onset. Here 'N' signifies subjects evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 (baseline) to Day 28

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	666	645		
Units: Subjects	507	483		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
-----------------------------------	---

Statistical analysis description:

Odds ratio, 95% CI and p-value were computed from a logistic regression model including main effects of treatment, geographic region, baseline SARS-CoV-2 serology status and baseline viral load (< 4 log10 copies/mL, >= 4 log10 copies/mL).

Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1311
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.5293
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.088
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.836
upper limit	1.416

Secondary: Number of Subjects With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT2 Population

End point title	Number of Subjects With Progression to a Worsening Status in 1 or More Self-reported COVID-19 Associated Symptoms Through Day 28-mITT2 Population
-----------------	---

End point description:

Subjects were required to record the severity of their Covid-19 symptoms over the past 24 hours daily on a 4-point scale where 0 = no symptoms; 1= mild; 2= moderate; and 3= severe. Vomiting and diarrhea were each rated on a 4-point frequency scale where 0= no occurrence, 1= mild for 1 to 2 times, 2= moderate for 3 to 4 times, and 3= severe for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline). mITT2 population included all subjects who were randomised and took at least one dose of study intervention. Here 'N' signifies subjects evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
From Day 1 (baseline) to Day 28	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1031	1050		
Units: Subjects	787	790		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
-----------------------------------	---

Statistical analysis description:

Odds ratio, 95% CI and p-value were computed from a logistic regression model including main effects of treatment, geographic region, symptom onset duration (≤ 3 , > 3), COVID-19 mAb treatment (Yes/No), baseline SARS-CoV-2 serology status and baseline viral load ($< 4 \log_{10}$ copies/mL, $\geq 4 \log_{10}$ copies/mL).

Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	2081
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.676
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.046
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.848
upper limit	1.29

Secondary: Percentage of Subjects With a Resting Peripheral Oxygen Saturation $\geq 95\%$ at Days 1 and 5- mITT Population

End point title	Percentage of Subjects With a Resting Peripheral Oxygen Saturation $\geq 95\%$ at Days 1 and 5- mITT Population
-----------------	---

End point description:

In this endpoint, the percentage of subjects with a resting peripheral oxygen saturation $\geq 95\%$ were reported. mITT population included all subjects who were randomized and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤ 3 days of COVID-19 onset. Here, n=signifies subjects evaluable for each specified categories.

End point type	Secondary
End point timeframe:	
Day 1, 5	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	671	647		
Units: Percentage of Subjects				
number (not applicable)				
Day 1; n=627,595	93.443	91.963		
Day 5; n=582,530	92.823	89.076		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Odds ratio for Day 5 vs Day 1: Placebo	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1318
Analysis specification	Pre-specified
Analysis type	
Method	Breslow-Day test
Parameter estimate	Odds ratio (OR)
Point estimate	8.948
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.159
upper limit	19.253

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Odds ratio for Day 5 vs Day 1: PF-07321332 300 mg + Ritonavir 100 mg	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo

Number of subjects included in analysis	1318
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.1997
Method	Breslow-Day test
Parameter estimate	Odds ratio (OR)
Point estimate	19.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	7.788
upper limit	48.328

Secondary: Percentage of Subjects With a Resting Peripheral Oxygen Saturation $\geq 95\%$ at Days 1 and 5- mITT1 Population

End point title	Percentage of Subjects With a Resting Peripheral Oxygen Saturation $\geq 95\%$ at Days 1 and 5- mITT1 Population
End point description:	In this endpoint, the percentage of subjects with a resting peripheral oxygen saturation $\geq 95\%$ were reported. mITT1 population included all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. Here, "n" signifies subjects evaluable for each specified time point.
End point type	Secondary
End point timeframe:	Day 1, 5

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	977	989		
Units: Percentage of Subjects				
number (not applicable)				
Day 1; n=912,912	93.347	92.214		
Day 5; n=835,799	91.557	87.610		

Statistical analyses

Statistical analysis title	Nirmatrelvir 300 mg + Ritonavir 100 mg
Statistical analysis description:	
Odds ratio for Day 5 vs Day 1: Placebo	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo

Number of subjects included in analysis	1966
Analysis specification	Pre-specified
Analysis type	
Method	Breslow Day test
Parameter estimate	Odds ratio (OR)
Point estimate	12.452
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.823
upper limit	22.725

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Odds ratio for Day 5 vs Day 1: PF-07321332 300 mg + Ritonavir 100 mg	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	1966
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.281
Method	Breslow-Day test
Parameter estimate	Odds ratio (OR)
Point estimate	20.875
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.097
upper limit	43.156

Secondary: Percentage of Subjects With a Resting Peripheral Oxygen Saturation $\geq 95\%$ at Days 1 and 5- mITT2 Population

End point title	Percentage of Subjects With a Resting Peripheral Oxygen Saturation $\geq 95\%$ at Days 1 and 5- mITT2 Population
End point description:	
In this endpoint, the percentage of subjects with a resting peripheral oxygen saturation $\geq 95\%$ were reported. mITT2 population included all subjects who were randomised and took at least one dose of study intervention. Here, "n" signifies subjects evaluable for each specified time point.	
End point type	Secondary
End point timeframe:	
Day 1, 5	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Percentage of Subjects				
number (not applicable)				
Day 1; n=969, 966	93.353	91.738		
Day 5; n=887, 847	91.538	87.681		

Statistical analyses

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Odds ratio for Day 5 vs Day 1: Placebo	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	2091
Analysis specification	Pre-specified
Analysis type	
Method	Breslow-Day test
Parameter estimate	Odds ratio (OR)
Point estimate	12.036
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.808
upper limit	21.28

Statistical analysis title	PF-07321332 300 mg and Ritonavir 100 mg
Statistical analysis description:	
Odds ratio for Day 5 vs Day 1: PF-07321332 300 mg + Ritonavir 100 mg	
Comparison groups	PF-07321332 300 mg and Ritonavir 100 mg v Placebo
Number of subjects included in analysis	2091
Analysis specification	Pre-specified
Analysis type	
P-value	= 0.2226
Method	Breslow-Day test
Parameter estimate	Odds ratio (OR)
Point estimate	21.119
Confidence interval	
level	95 %
sides	2-sided
lower limit	10.412
upper limit	42.837

Secondary: Percentage of Subjects Who Died Through Week 24- mITT Population

End point title	Percentage of Subjects Who Died Through Week 24- mITT Population
-----------------	--

End point description:

In this endpoint, percentage of subjects with death due to any cause was presented. mITT population included all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤ 3 days of COVID-19 onset.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 up to Week 24

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	671	647		
Units: Percentage of Subjects				
number (not applicable)	0	1.7		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Died Through Week 24- mITT2 Population

End point title	Percentage of Subjects Who Died Through Week 24- mITT2 Population
-----------------	---

End point description:

In this endpoint, percentage of subjects with death due to any cause was presented. mITT2 population included all subjects who were randomised and took at least one dose of study intervention.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 up to Week 24

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Percentage of Subjects				
number (not applicable)	0	1.4		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects Who Died Through Week 24- mITT1 Population

End point title	Percentage of Subjects Who Died Through Week 24- mITT1 Population
-----------------	---

End point description:

In this endpoint, percentage of Subjects with death due to any cause was presented. mITT1 population included all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment.

End point type	Secondary
----------------	-----------

End point timeframe:

From Day 1 up to Week 24

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	977	989		
Units: Percentage of Subjects				
number (not applicable)	0	1.5		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentration Versus Time Summary of PF-07321332

End point title	Plasma Concentration Versus Time Summary of PF-07321332 ^[1]
-----------------	--

End point description:

SAS population included all subjects who were randomized and took at least one dose of study intervention. Here "Overall Number of subjects Analyzed" signifies subjects evaluable for this endpoint. Here "n" signifies subjects evaluable for the specified time point.

End point type	Secondary
----------------	-----------

End point timeframe:

1 Hour post-dose on Day 1 and pre-dose on Day 5

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was analyzed only for specified reporting arms.

End point values	PF-07321332 300 mg and Ritonavir 100 mg			
Subject group type	Reporting group			
Number of subjects analysed	772			
Units: Nanograms per milliliter				
arithmetic mean (standard deviation)				
Day 1 (1 Hour post dose); n=267	2201 (± 2130.7)			
Day 5 (Pre-dose); n=505	3087 (± 2884.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Logarithm to Base10 (Log10) Transformed Viral Load at Day 3, 5, 10 and 14- mITT Population

End point title	Change From Baseline in Logarithm to Base10 (Log10) Transformed Viral Load at Day 3, 5, 10 and 14- mITT Population
-----------------	--

End point description:

The viral load was measured in nasal or nasopharyngeal samples using reverse transcription polymerase chain reaction (RT-PCR). mITT population included all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤3 days of COVID-19 onset. Here "Overall Number of Subjects Analyzed" signifies subjects evaluable for this endpoint. Here, "n" signifies subjects evaluable for each specified time point.

End point type	Secondary
End point timeframe:	
Baseline, Day 3, 5, 10 and 14	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	671	647		
Units: Log10 copies per milliliter				
arithmetic mean (standard deviation)				
Day 3; n=509,498	-1.829 (± 1.805)	-1.203 (± 1.697)		
Day 5; n=487,478	-3.244 (± 1.697)	-2.293 (± 1.787)		
Day 10; n=482,447	-4.522 (± 2.105)	-3.964 (± 2.115)		
Day 14; n=486,472	-5.108 (± 2.141)	-4.862 (± 2.121)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Log10 Transformed Viral Load at Day 3, 5, 10 and 14- mITT1 Population

End point title	Change From Baseline in Log10 Transformed Viral Load at Day 3, 5, 10 and 14- mITT1 Population
-----------------	---

End point description:

The viral load was measured in nasal or nasopharyngeal samples using RT-PCR. mITT1 population included all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. Here "Overall Number of Subjects Analyzed" signifies subjects evaluable for this endpoint. Here, "n" signifies subjects evaluable for each specified time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Day 3, 5, 10 and 14

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	977	989		
Units: Log10 copies per milliliter				
arithmetic mean (standard deviation)				
Day 3; n=718,733	-1.790 (± 1.727)	-1.182 (± 1.689)		
Day 5; n=688,694	-3.064 (± 1.708)	-2.213 (± 1.754)		
Day 10; n=682,663	-4.309 (± 2.108)	-3.772 (± 2.058)		
Day 14; n=691,698	-4.878 (± 2.144)	-4.556 (± 2.146)		

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Log10 Transformed Viral Load at Day 3, 5, 10 and 14- mITT2 Population

End point title	Change From Baseline in Log10 Transformed Viral Load at Day 3, 5, 10 and 14- mITT2 Population
-----------------	---

End point description:

The viral load was measured in nasal or nasopharyngeal samples using RT-PCR. mITT2 population included all subjects who were randomised and took at least one dose of study intervention. Here, "n" signifies subjects evaluable for each specified time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Day 3, 5, 10 and 14

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Log10 copies per milliliter				
arithmetic mean (standard deviation)				
Day 3; n=766,781	-1.828 (± 1.715)	-1.178 (± 1.663)		
Day 5; n=735,743	-3.097 (± 1.692)	-2.239 (± 1.741)		
Day 10; n=728,712	-4.322 (± 2.109)	-3.777 (± 2.041)		
Day 14; n=739,752	-4.882 (± 2.142)	-4.547 (± 2.146)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of COVID-19 Related Medical Visits- mITT Population

End point title	Number of COVID-19 Related Medical Visits- mITT Population
End point description:	
Medical visits included emergency room, practitioner's office, home healthcare services, urgent care, telephone consultation, outpatient infusion center, other, COVID-19-related-hospitalisation (intensive care unit [ICU] and non-ICU stays). In this outcome measure, COVID-19-related medical visits of subjects were reported. mITT population included all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤3 days of COVID-19 onset.	
End point type	Secondary
End point timeframe:	
From Day 1 up to Day 34	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	671	647		
Units: Visits	22	81		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of COVID-19 Related Medical Visits- mITT1 Population

End point title	Number of COVID-19 Related Medical Visits- mITT1 Population
End point description: Medical visits included emergency room, practitioner's office, home healthcare services, urgent care, telephone consultation, outpatient infusion center, other, COVID-19-related-hospitalisation (ICU and non-ICU stays). In this outcome measure, COVID-19-related medical visits of subjects were reported. mITT1 population included all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment.	
End point type	Secondary
End point timeframe: From Day 1 up to Day 34	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	977	989		
Units: Visits	40	128		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of COVID-19 Related Medical Visits- mITT2 Population

End point title	Number of COVID-19 Related Medical Visits- mITT2 Population
End point description: Medical visits included emergency room, practitioner's office, home healthcare services, urgent care, telephone consultation, outpatient infusion center, other, COVID-19-related-hospitalisation (ICU and non-ICU stays). In this outcome measure, COVID-19-related medical visits of subjects were reported. mITT2 population included all subjects who were randomised and took at least one dose of study intervention.	
End point type	Secondary
End point timeframe: From Day 1 up to Day 34	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Visits	45	144		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT Population

End point title	Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT Population
End point description: mITT population included all subjects who were randomised and took at least one dose of study intervention, who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment and were treated ≤ 3 days of COVID-19 onset. The analysis was performed on all subjects (i.e. hospitalised and non-hospitalised subjects were included).	
End point type	Secondary
End point timeframe: From Day 1 up to Day 34	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	671	647		
Units: Days				
arithmetic mean (standard deviation)				
Duration of hospitalisation visits	0.088 (\pm 1.049)	0.844 (\pm 4.535)		
Duration of ICU visits	0.000 (\pm 0.000)	0.179 (\pm 2.389)		
Duration of non-ICU visits	0.088 (\pm 1.049)	0.666 (\pm 3.710)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT1 Population

End point title	Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT1 Population
End point description: mITT1 population included all subjects who were randomised and took at least one dose of study intervention and who at baseline did not receive nor were expected to receive COVID-19 therapeutic mAb treatment. The analysis was performed on all subjects (i.e. hospitalised and non-hospitalised	

subjects were included).

End point type	Secondary
End point timeframe:	
From Day 1 up to Day 34	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	977	989		
Units: Days				
arithmetic mean (standard deviation)				
Duration of hospitalisation visits	0.087 (± 0.968)	0.766 (± 4.055)		
Duration of ICU visits	0.000 (± 0.000)	0.128 (± 1.964)		
Duration of non-ICU visits	0.087 (± 0.968)	0.639 (± 3.446)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT2 Population

End point title	Number of Days in Hospital and ICU for the Treatment of COVID-19- mITT2 Population
-----------------	--

End point description:

mITT2 population included all subjects who were randomised and took at least one dose of study intervention. The analysis was performed on all subjects (i.e. hospitalised and non-hospitalised subjects were included).

End point type	Secondary
End point timeframe:	
From Day 1 up to Day 34	

End point values	PF-07321332 300 mg and Ritonavir 100 mg	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1038	1053		
Units: Days				
arithmetic mean (standard deviation)				
Duration of hospitalisation visits	0.092 (± 0.988)	0.729 (± 3.940)		
Duration of ICU visits	0.000 (± 0.000)	0.121 (± 1.904)		

Duration of non-ICU visits	0.092 (± 0.988)	0.610 (± 3.350)		
----------------------------	--------------------	--------------------	--	--

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From start of study intervention at Day 1 up to end of long-term safety follow-up (Week 24)

Adverse event reporting additional description:

Same event may appear as both AE and SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 subject and as non-serious in another subject, or 1 subject may have experienced both serious and non-serious event during the study.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects with SARS-CoV-2 infection received placebo orally, q12h for 5 days. Subjects were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24.

Reporting group title	PF-07321332 300 mg + Ritonavir 100 mg
-----------------------	---------------------------------------

Reporting group description:

Subjects with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection received 300 milligrams (mg) PF-07321332 coadministered with 100 mg ritonavir orally, q12h for 5 days. Subjects were followed up for safety up to Day 34 and long-term safety follow up was up to Week 24.

Serious adverse events	Placebo	PF-07321332 300 mg + Ritonavir 100 mg	
Total subjects affected by serious adverse events			
subjects affected / exposed	72 / 1053 (6.84%)	19 / 1038 (1.83%)	
number of deaths (all causes)	15	0	
number of deaths resulting from adverse events			
Investigations			
Oxygen saturation decreased			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemoglobin decreased			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibrin D dimer increased			

subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Creatinine renal clearance decreased			
subjects affected / exposed	2 / 1053 (0.19%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Alanine aminotransferase increased			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon adenoma			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Wrist fracture			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Road traffic accident			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hand fracture			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye injury			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Craniocerebral injury			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertensive crisis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Facial paralysis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain stem stroke			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pregnancy, puerperium and perinatal conditions			
Abortion threatened			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			

Chest discomfort			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Rectal haemorrhage			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Respiratory failure			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	2 / 1053 (0.19%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	5 / 1053 (0.47%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 7	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Interstitial lung disease			
subjects affected / exposed	2 / 1053 (0.19%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	2 / 1053 (0.19%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Dyspnoea			
subjects affected / exposed	3 / 1053 (0.28%)	2 / 1038 (0.19%)	
occurrences causally related to treatment / all	0 / 3	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Acute respiratory failure			
subjects affected / exposed	5 / 1053 (0.47%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 5	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Nasal obstruction			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Sepsis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	11 / 1053 (1.04%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 11	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abscess			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atypical pneumonia			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
COVID-19			
subjects affected / exposed	7 / 1053 (0.66%)	2 / 1038 (0.19%)	
occurrences causally related to treatment / all	0 / 10	0 / 2	
deaths causally related to treatment / all	0 / 3	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	36 / 1053 (3.42%)	7 / 1038 (0.67%)	
occurrences causally related to treatment / all	0 / 44	0 / 7	
deaths causally related to treatment / all	0 / 8	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Placebo	PF-07321332 300 mg + Ritonavir 100 mg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	228 / 1053 (21.65%)	234 / 1038 (22.54%)	
Vascular disorders			
Vein collapse			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Deep vein thrombosis			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Embolism			
subjects affected / exposed	2 / 1053 (0.19%)	0 / 1038 (0.00%)	
occurrences (all)	2	0	
Hyperaemia			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Hypertension			
subjects affected / exposed	4 / 1053 (0.38%)	8 / 1038 (0.77%)	
occurrences (all)	4	8	
Hypotension			
subjects affected / exposed	4 / 1053 (0.38%)	1 / 1038 (0.10%)	
occurrences (all)	4	1	
Orthostatic hypotension			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Thrombophlebitis			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	3 / 1053 (0.28%)	3 / 1038 (0.29%)	
occurrences (all)	3	3	
Catheter site pain			

subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Chest discomfort			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Chest pain			
subjects affected / exposed	1 / 1053 (0.09%)	2 / 1038 (0.19%)	
occurrences (all)	1	2	
Chills			
subjects affected / exposed	0 / 1053 (0.00%)	5 / 1038 (0.48%)	
occurrences (all)	0	5	
Fatigue			
subjects affected / exposed	5 / 1053 (0.47%)	2 / 1038 (0.19%)	
occurrences (all)	5	2	
Non-cardiac chest pain			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Oedema due to cardiac disease			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Pain			
subjects affected / exposed	3 / 1053 (0.28%)	0 / 1038 (0.00%)	
occurrences (all)	3	0	
Peripheral swelling			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Pyrexia			
subjects affected / exposed	7 / 1053 (0.66%)	8 / 1038 (0.77%)	
occurrences (all)	7	8	
Immune system disorders			
Mycotic allergy			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Seasonal allergy			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	

Social circumstances Disease risk factor subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Reproductive system and breast disorders Vaginal haemorrhage subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	1 / 1038 (0.10%) 1	
Intermenstrual bleeding subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Heavy menstrual bleeding subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Asthma subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	1 / 1038 (0.10%) 1	
Acute respiratory failure subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Allergic cough subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Hiccups subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Dyspnoea subjects affected / exposed occurrences (all)	7 / 1053 (0.66%) 8	7 / 1038 (0.67%) 7	
Epistaxis subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	1 / 1038 (0.10%) 1	
Haemoptysis subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	

Hypoxia			
subjects affected / exposed	3 / 1053 (0.28%)	0 / 1038 (0.00%)	
occurrences (all)	3	0	
Interstitial lung disease			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Nasal congestion			
subjects affected / exposed	0 / 1053 (0.00%)	4 / 1038 (0.39%)	
occurrences (all)	0	4	
Oropharyngeal pain			
subjects affected / exposed	0 / 1053 (0.00%)	5 / 1038 (0.48%)	
occurrences (all)	0	5	
Pulmonary mass			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Rhinorrhoea			
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)	
occurrences (all)	1	1	
Cough			
subjects affected / exposed	6 / 1053 (0.57%)	6 / 1038 (0.58%)	
occurrences (all)	6	6	
Psychiatric disorders			
Stress			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Insomnia			
subjects affected / exposed	2 / 1053 (0.19%)	2 / 1038 (0.19%)	
occurrences (all)	2	2	
Depression			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Confusional state			
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)	
occurrences (all)	1	1	
Anxiety			

subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	3 / 1038 (0.29%) 3	
Product issues Product after taste subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	3 / 1038 (0.29%) 3	
Investigations C-reactive protein subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	2 / 1038 (0.19%) 2	
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	12 / 1053 (1.14%) 13	9 / 1038 (0.87%) 9	
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	26 / 1053 (2.47%) 26	18 / 1038 (1.73%) 19	
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	14 / 1053 (1.33%) 14	11 / 1038 (1.06%) 12	
Blood albumin decreased subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Blood bicarbonate decreased subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	1 / 1038 (0.10%) 1	
Blood calcium decreased subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Blood calcium increased subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Blood creatine phosphokinase increased			

subjects affected / exposed	5 / 1053 (0.47%)	1 / 1038 (0.10%)
occurrences (all)	5	1
Blood creatinine decreased		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Blood creatinine increased		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Blood fibrinogen decreased		
subjects affected / exposed	3 / 1053 (0.28%)	5 / 1038 (0.48%)
occurrences (all)	3	5
Blood glucose decreased		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Blood glucose increased		
subjects affected / exposed	7 / 1053 (0.66%)	1 / 1038 (0.10%)
occurrences (all)	7	2
Blood lactate dehydrogenase increased		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Blood potassium increased		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Blood pressure increased		
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)
occurrences (all)	1	1
Blood sodium decreased		
subjects affected / exposed	2 / 1053 (0.19%)	0 / 1038 (0.00%)
occurrences (all)	2	0
Blood thyroid stimulating hormone decreased		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Blood thyroid stimulating hormone increased		

subjects affected / exposed	7 / 1053 (0.66%)	5 / 1038 (0.48%)
occurrences (all)	8	5
Blood urea increased		
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)
occurrences (all)	1	1
Breath sounds abnormal		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
C-reactive protein increased		
subjects affected / exposed	13 / 1053 (1.23%)	10 / 1038 (0.96%)
occurrences (all)	13	10
Coagulation time prolonged		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Creatinine renal clearance decreased		
subjects affected / exposed	14 / 1053 (1.33%)	14 / 1038 (1.35%)
occurrences (all)	14	15
Creatinine renal clearance increased		
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)
occurrences (all)	1	1
Differential white blood cell count abnormal		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Fibrin D dimer		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	2
Fibrin D dimer increased		
subjects affected / exposed	30 / 1053 (2.85%)	25 / 1038 (2.41%)
occurrences (all)	30	26
Glomerular filtration rate abnormal		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Glomerular filtration rate decreased		
subjects affected / exposed	2 / 1053 (0.19%)	3 / 1038 (0.29%)
occurrences (all)	2	3

Glycosylated haemoglobin increased subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0
Haematocrit increased subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	1 / 1038 (0.10%) 1
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1
Haemoglobin increased subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0
Haptoglobin increased subjects affected / exposed occurrences (all)	3 / 1053 (0.28%) 3	4 / 1038 (0.39%) 4
Hepatic enzyme abnormal subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0
Hepatic enzyme increased subjects affected / exposed occurrences (all)	3 / 1053 (0.28%) 3	2 / 1038 (0.19%) 2
Hepatitis C virus test positive subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1
International normalised ratio abnormal subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1
International normalised ratio increased subjects affected / exposed occurrences (all)	5 / 1053 (0.47%) 5	3 / 1038 (0.29%) 3
Lymphocyte count decreased subjects affected / exposed occurrences (all)	3 / 1053 (0.28%) 3	0 / 1038 (0.00%) 0
Neutrophil count decreased		

subjects affected / exposed	2 / 1053 (0.19%)	0 / 1038 (0.00%)
occurrences (all)	2	0
Neutrophil count increased		
subjects affected / exposed	0 / 1053 (0.00%)	2 / 1038 (0.19%)
occurrences (all)	0	2
Oxygen saturation decreased		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Platelet count decreased		
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)
occurrences (all)	1	1
Platelet count increased		
subjects affected / exposed	1 / 1053 (0.09%)	2 / 1038 (0.19%)
occurrences (all)	1	2
Procalcitonin increased		
subjects affected / exposed	2 / 1053 (0.19%)	1 / 1038 (0.10%)
occurrences (all)	2	1
Prothrombin time prolonged		
subjects affected / exposed	5 / 1053 (0.47%)	3 / 1038 (0.29%)
occurrences (all)	5	3
Red blood cell count increased		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Serum ferritin decreased		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Serum ferritin increased		
subjects affected / exposed	6 / 1053 (0.57%)	2 / 1038 (0.19%)
occurrences (all)	6	2
Thyroxine free increased		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Thyroxine increased		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Transaminases increased		

subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
White blood cell count increased subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	2 / 1038 (0.19%) 2	
White blood cell count decreased subjects affected / exposed occurrences (all)	3 / 1053 (0.28%) 3	2 / 1038 (0.19%) 2	
Weight increased subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	2 / 1053 (0.19%) 2	0 / 1038 (0.00%) 0	
Hand fracture subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Ligament rupture subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Meniscus injury subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Cardiac disorders			
Palpitations subjects affected / exposed occurrences (all)	2 / 1053 (0.19%) 2	1 / 1038 (0.10%) 1	
Pericardial effusion subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Sinus bradycardia subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Sinus tachycardia			

subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Ventricular arrhythmia subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Nervous system disorders			
Vascular dementia subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Tremor subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Tension headache subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Syncope subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Restless legs syndrome subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Parosmia subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Paraesthesia subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Memory impairment subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Hypersomnia subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	13 / 1053 (1.23%) 13	12 / 1038 (1.16%) 17	

Facial paralysis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Dysgeusia			
subjects affected / exposed	1 / 1053 (0.09%)	48 / 1038 (4.62%)	
occurrences (all)	1	48	
Dizziness			
subjects affected / exposed	5 / 1053 (0.47%)	3 / 1038 (0.29%)	
occurrences (all)	5	3	
Anosmia			
subjects affected / exposed	0 / 1053 (0.00%)	3 / 1038 (0.29%)	
occurrences (all)	0	3	
Amnesia			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 1053 (0.19%)	1 / 1038 (0.10%)	
occurrences (all)	2	1	
Leukopenia			
subjects affected / exposed	2 / 1053 (0.19%)	2 / 1038 (0.19%)	
occurrences (all)	2	2	
Lymphadenopathy mediastinal			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Microcytic anaemia			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Neutropenia			
subjects affected / exposed	2 / 1053 (0.19%)	0 / 1038 (0.00%)	
occurrences (all)	2	0	
Thrombocytopenia			
subjects affected / exposed	3 / 1053 (0.28%)	0 / 1038 (0.00%)	
occurrences (all)	3	0	
Leukocytosis			

subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	2 / 1038 (0.19%) 2	
Ear and labyrinth disorders			
Hyperacusis			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Vertigo			
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)	
occurrences (all)	1	1	
Eye disorders			
Eye pain			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal pain lower			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Abdominal pain			
subjects affected / exposed	3 / 1053 (0.28%)	2 / 1038 (0.19%)	
occurrences (all)	3	2	
Abdominal pain upper			
subjects affected / exposed	2 / 1053 (0.19%)	5 / 1038 (0.48%)	
occurrences (all)	2	5	
Colitis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Constipation			
subjects affected / exposed	3 / 1053 (0.28%)	1 / 1038 (0.10%)	
occurrences (all)	3	1	
Diarrhoea			
subjects affected / exposed	16 / 1053 (1.52%)	31 / 1038 (2.99%)	
occurrences (all)	19	32	
Dyspepsia			
subjects affected / exposed	4 / 1053 (0.38%)	4 / 1038 (0.39%)	
occurrences (all)	4	4	
Faeces soft			

subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Gastritis			
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)	
occurrences (all)	1	1	
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 1053 (0.09%)	2 / 1038 (0.19%)	
occurrences (all)	1	2	
Hiatus hernia			
subjects affected / exposed	2 / 1053 (0.19%)	0 / 1038 (0.00%)	
occurrences (all)	2	0	
Hyperchlorhydria			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Large intestine polyp			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Nausea			
subjects affected / exposed	19 / 1053 (1.80%)	15 / 1038 (1.45%)	
occurrences (all)	20	16	
Toothache			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	9 / 1053 (0.85%)	12 / 1038 (1.16%)	
occurrences (all)	9	12	
Aphthous ulcer			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Hepatic function abnormal			
subjects affected / exposed	1 / 1053 (0.09%)	2 / 1038 (0.19%)	
occurrences (all)	1	2	
Cholestasis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	

Hepatic steatosis			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Hyperbilirubinaemia			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Liver injury			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Steatohepatitis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Hepatitis toxic			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)	
occurrences (all)	1	0	
Alopecia			
subjects affected / exposed	3 / 1053 (0.28%)	1 / 1038 (0.10%)	
occurrences (all)	3	1	
Erythema			
subjects affected / exposed	4 / 1053 (0.38%)	0 / 1038 (0.00%)	
occurrences (all)	4	0	
Hyperhidrosis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	2	
Hyperkeratosis			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Pruritus			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	
Rash			

subjects affected / exposed occurrences (all)	3 / 1053 (0.28%) 3	2 / 1038 (0.19%) 2	
Rash maculo-papular subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Skin exfoliation subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	2 / 1038 (0.19%) 2	
Skin oedema subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Urticaria subjects affected / exposed occurrences (all)	2 / 1053 (0.19%) 2	0 / 1038 (0.00%) 0	
Renal and urinary disorders Renal impairment subjects affected / exposed occurrences (all)	2 / 1053 (0.19%) 2	0 / 1038 (0.00%) 0	
Nephrosclerosis subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Chronic kidney disease subjects affected / exposed occurrences (all)	2 / 1053 (0.19%) 2	1 / 1038 (0.10%) 1	
Endocrine disorders Thyroiditis chronic subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Musculoskeletal and connective tissue disorders Pain in extremity subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	1 / 1038 (0.10%) 1	
Myalgia subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	7 / 1038 (0.67%) 7	
Musculoskeletal stiffness			

subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Muscle spasms subjects affected / exposed occurrences (all)	2 / 1053 (0.19%) 2	0 / 1038 (0.00%) 0	
Intervertebral disc protrusion subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Intervertebral disc degeneration subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Fibromyalgia subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Back pain subjects affected / exposed occurrences (all)	3 / 1053 (0.28%) 3	2 / 1038 (0.19%) 2	
Arthralgia subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	3 / 1038 (0.29%) 4	
Spinal osteoarthritis subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Infections and infestations Urinary tract infection subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	1 / 1038 (0.10%) 1	
Bronchitis subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	1 / 1038 (0.10%) 1	
Bronchopulmonary aspergillosis subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
COVID-19 subjects affected / exposed occurrences (all)	7 / 1053 (0.66%) 7	7 / 1038 (0.67%) 7	

COVID-19 pneumonia		
subjects affected / exposed	6 / 1053 (0.57%)	1 / 1038 (0.10%)
occurrences (all)	6	1
Gastroenteritis viral		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Hepatitis viral		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Influenza		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Mumps		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Nasopharyngitis		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Oral candidiasis		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Oral herpes		
subjects affected / exposed	2 / 1053 (0.19%)	1 / 1038 (0.10%)
occurrences (all)	2	1
Oropharyngeal candidiasis		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Pharyngitis		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Pneumonia		
subjects affected / exposed	4 / 1053 (0.38%)	1 / 1038 (0.10%)
occurrences (all)	4	1
Pneumonia viral		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0

Pyelonephritis chronic subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Respiratory tract infection bacterial subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Respiratory tract infection viral subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	2 / 1038 (0.19%) 2	
Staphylococcal bacteraemia subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Tonsillitis subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Viral rhinitis subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Viral sepsis subjects affected / exposed occurrences (all)	0 / 1053 (0.00%) 0	1 / 1038 (0.10%) 1	
Metabolism and nutrition disorders			
Type 2 diabetes mellitus subjects affected / exposed occurrences (all)	4 / 1053 (0.38%) 4	1 / 1038 (0.10%) 1	
Lack of satiety subjects affected / exposed occurrences (all)	1 / 1053 (0.09%) 1	0 / 1038 (0.00%) 0	
Impaired fasting glucose			

subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Hypophosphataemia		
subjects affected / exposed	1 / 1053 (0.09%)	1 / 1038 (0.10%)
occurrences (all)	1	1
Hyponatraemia		
subjects affected / exposed	0 / 1053 (0.00%)	2 / 1038 (0.19%)
occurrences (all)	0	2
Hypomagnesaemia		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Hypokalaemia		
subjects affected / exposed	3 / 1053 (0.28%)	3 / 1038 (0.29%)
occurrences (all)	4	3
Hypervolaemia		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Hypertriglyceridaemia		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Hyperkalaemia		
subjects affected / exposed	1 / 1053 (0.09%)	0 / 1038 (0.00%)
occurrences (all)	1	0
Hyperglycaemia		
subjects affected / exposed	4 / 1053 (0.38%)	2 / 1038 (0.19%)
occurrences (all)	4	2
Gout		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Glucose tolerance impaired		
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)
occurrences (all)	0	1
Diabetes mellitus inadequate control		
subjects affected / exposed	1 / 1053 (0.09%)	2 / 1038 (0.19%)
occurrences (all)	1	2
Diabetes mellitus		

subjects affected / exposed	0 / 1053 (0.00%)	2 / 1038 (0.19%)	
occurrences (all)	0	2	
Dehydration			
subjects affected / exposed	1 / 1053 (0.09%)	2 / 1038 (0.19%)	
occurrences (all)	1	2	
Decreased appetite			
subjects affected / exposed	0 / 1053 (0.00%)	1 / 1038 (0.10%)	
occurrences (all)	0	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 November 2021	To remove the second interim analysis (70% interim analysis that was added under Amendment 3) from the protocol because the objective of the planned 45% interim analysis was met.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported